课题基金 / 基金详情

Establishment of a novel IFN therapy with little side effects

Establishment of a novel IFN therapy with little side effects
建立一种副作用小的新型干扰素疗法
批准号:
17390277
负责人:
ORITANI Kenji
金额:
$9.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006

项目摘要

项目成果

ORITANI Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our identified IFN-ζ/Limitin has similar anti-viral and immunomoduratory activities to IFN-a. However, IFN-ζ/Limitin failed to suppress colony formation of CFU-GM, BFU-E, and CFU-Meg. Although less myelo-suppressive property may suggest wide range of clinical utility of IFN-ζ/Limitin, human homologue of IFN-ζ/Limitin has not been identified yet. There are unique amino acid residues in receptor-binding sites of IFN-ζ/Limitin when compared with IFN-α and IFN-β. To identify responsible amino acid residues for the different biological activities between IFN-t/Lmitin and IFN-α, we constructed several mutated IFN-α (ml-m7-IFN-a) whose amino acid residues were substituted by those of IFN-ζ/Limitin, and compared biological activities of the mutated IFN-as with those of original IFN-α. m3-IFN-α carrying three amino acids substitution in the AB loop has revealed less suppressive effects on colony formation of CFU-GM and BFU-E, while it has similar anti-viral activity to IFN-α. Little myelo-suppr … More essive property of m3-IFN-α was also confirmed by the injection to mice. On the other hand, ml-IFN-α carrying four amino acids substitution in the herix C has revealed higher anti-viral activity than original IFN-α. The other mutated IFN-αs lost both anti-viral and myelo-suppressive activities. These results are useful to construct a novel human IFN, which has IFN-ζ/Limitin-like characters.We have analyzed IFN-signals, which mediate myelo-suppressive activities, and have clarified essential roles of Tyk2 and Daxx. Reduction of protein expression of Tyk2 and/or Daxx by antisense oligonucleotides resulted in lack of myelo-suppressive activities of IFN-α. In addition, a sumoylation-defective Daxx KA mutant (Daxx K630/631A) localized in the cytoplasm, whereas wild-type Daxx localized in the nucleus. Murine pro-B cell line Ba/F3 expressing Daxx KA revealed a resistance to IFN-induced growth suppression, indicating the important role of sumoylation of Daxx in IFN-induced myelo-suppression. These results are useful to design a strategy for the IFN-therapy. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2005
期刊: Journal of cellular and molecular medicine
影响因子: 5.3
作者: [K. Oritani;Y. Kanakura]
通讯作者: K. Oritani;Y. Kanakura
Differential effects of a novel IFN-zeta/limitin and IFN-alphs on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes.
新型 IFN-zeta/limitin 和 IFN-α 对 Daxx 诱导和 Crk 磷酸化信号的不同影响,与巨核细胞的生长控制相结合。
DOI: --
发表时间: 2005
期刊: Exp Hematol 33(4)
影响因子: --
作者: [Oritani K, et al., Oritani K et al., Ishida N et al.]
通讯作者: Ishida N et al.
DOI: 10.1038/sj.onc.1209235
发表时间: 2006-03-01
期刊: ONCOGENE
影响因子: 8
作者: [Muromoto, R, Nakao, K, Matsuda, T]
通讯作者: Matsuda, T
DOI: 10.1002/jcb.20779
发表时间: 2006-05
期刊: Journal of Cellular Biochemistry
影响因子: 4
作者: [H. Ujiie;K. Oritani;H. Kato;T. Yokota;Isao Takahashi;T. Maeda;H. Masaie;M. Ichii;Y. Kamada;S. Tamura;S. Kihara;T. Funahashi;Y. Tomiyama;Y. Kanakura]
通讯作者: H. Ujiie;K. Oritani;H. Kato;T. Yokota;Isao Takahashi;T. Maeda;H. Masaie;M. Ichii;Y. Kamada;S. Tamura;S. Kihara;T. Funahashi;Y. Tomiyama;Y. Kanakura
6
    Analysis of in vivo effects of possible immune regulatory moleculesfor artificial management of immune systems
    • 批准号:
      22591062
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2010
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Development of a novel interferon with mild adverse effects
    • 批准号:
      19390264
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.98万
    • 财政年份:
      2007
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
    • 批准号:
      15390300
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.47万
    • 财政年份:
      2003
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Biological activity of limitin and adiponectin
    • 批准号:
      13671064
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.56万
    • 财政年份:
      2001
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    国内基金
    海外基金
    系统性探索不同N-glycan修饰对Interferonβ活性和稳定性影响
    • 批准号:
      21877063
    • 项目类别:
      面上项目
    • 资助金额:
      61.4万元
    • 批准年份:
      2018
    • 负责人:
      王鹏
    • 依托单位:
    控制肠道病毒71型感染的先天性免疫保护机制及其应用
    干扰素信号分子及其调控网络在抗HBV感染过程中的作用机制研究
    • 批准号:
      81171558
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2011
    • 负责人:
      宁琴
    • 依托单位:
    糖药物蛋白Interferonβ N-glycan的均一、人源化改造
    • 批准号:
      81102361
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      25.0万元
    • 批准年份:
      2011
    • 负责人:
      程剑松
    • 依托单位: